For many years JMP software has been used for interactive visualization and statistical research of cancer. Within the JMP group, in particular the JMP Life Sciences group, we discuss the importance of helping our customers perform their research with the latest methods available for doing so. You don't have to take my word for it though, a quick search within google scholar makes it easy to see the value of JMP software for studying cancer: Google Scholar search of: "JMP software" + "cancer" These journal articles provide examples of the comprehensive nature of the visualization and analyses that can be done within JMP to conduct research in the oncology field.
There is a white paper on Classification of Breast Cancer Cells using JMP, by Marie Gaudard of the North Haven Group, which you can download from here: Classification of Breast Cancer Cells using JMP. There are many more examples to choose from if you search discussions in community.jmp.com, I can provide a starting link here: Search JMP Community for Cancer.
You may also be familiar with our JMP Genomics product which is especially designed for disentangling signals from biomarkers, expression patterns, next-gen sequence data as well as rare and common variants in cancer studies. Another google scholar search Google Scholar of "JMP Genomics" + "cancer" provides a peek into one of the most sophisticated tools for analyzing data from Dr. Russell Wolfinger and his JMP Life Science team's body of research using Predictive Modeling. Nearly everyone on his team has a wide variety of publications in the genomics world.
A seminar on reproducible experimentation for diagnostically driven drugs in cancer research by Matthew Wongchenko (Genentech) and Russell Wolfinger (JMP) can be seen here: Reproducible Experimentation for Diagnostically Driven Drug Research.
While JMP Clinical was developed to evaluate the safety and efficacy for all clinical trials, our customers have asked us to develop more specific reports to evaluate cancer trials. The importance of cancer studies is reflected with the introduction of a new guidance on the safety and efficacy endpoints for oncology in clinical trials at the end of 2018 by the US FDA: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Many of the endpoints can be evaluated directly in JMP Clinical 7, with a variety of new visualizations including swimmer plots, waterfall plots, forest plots and spider plots. A new video by my colleague, Dr. Kelci Miclaus, highlights the value of JMP Clinical 7 for these type of studies: Visualization and Analysis in Oncology Trials Using RECIST. You can also visit our new JMP Clinical Website which has been updated to reflect the new features for cancer studies.
Stay tuned for more JMP and JMP Clinical enhancements later this spring as we learn even more from our customers about how they evaluate the cancer data.
